The platelet P2 receptors in inflammation

Hamostaseologie

Volumn 35, Issue 3, 2015, Pages 262-266

  Cattaneo, Marco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Asthma; Cysteinyl leukotrien; Inflammation; P2Y12; Platelets

Indexed keywords

ADENINE NUCLEOTIDE; CD4 ANTIGEN; CD40 LIGAND; PEPTIDOLEUKOTRIENE; PURINERGIC P2 RECEPTOR; THROMBOCYTE RECEPTOR; ADENOSINE DIPHOSPHATE; PURINERGIC P2Y2 RECEPTOR;

AIRWAY REMODELING; ALLERGIC ASTHMA; AMINO TERMINAL SEQUENCE; BRONCHOCONSTRICTION; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE; COHORT ANALYSIS; HELPER CELL; HUMAN; INFLAMMATION; LUNG FUNCTION; NONHUMAN; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE FUNCTION; VASCULITIS; ANIMAL; ASTHMA; BIOLOGICAL MODEL; IMMUNOLOGY; INNATE IMMUNITY; THROMBOCYTE ACTIVATION;

ADENOSINE DIPHOSPHATE; ANIMALS; ASTHMA; BLOOD PLATELETS; HUMANS; IMMUNITY, INNATE; MODELS, IMMUNOLOGICAL; PLATELET ACTIVATION; RECEPTORS, PURINERGIC P2Y2;

EID: 84931072422     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/HAMO-14-09-0044     Document Type: Review

References (76)

1. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-274.
2. Amison R, Page C, Pitchford S. Pharmacological modulation of the inflammatory actions of platelets. Handb Exp Pharmacol 2012: 447-468.
3. Ware J, Corken A, Khetpal R. Platelet function beyond hemostasis and thrombosis. Curr Opin Hematol 2013; 20: 451-456.
4. Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood 2014; 123: 2759-2767.
5. Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115: 3427-3436.
6. Müller F, Mutch NJ, Schenk WA et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139:1143-1156.
7. Shi G, Field DJ, Ko KA et al. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. J Clin Invest 2014; 124: 543-552.
8. Von Hundelshausen P, Weber KS, Huo Y et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 1772-1777.
9. Boilard E, Nigrovic PA, Larabee K et al. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010; 327: 580-583.
10. Zimmerman GA, Weyrich AS. Immunology. Arsonists in rheumatoid arthritis. Science 2010; 327:528-529.
11. Langer HF, Choi EY, Zhou H et al. Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res 2012; 110:1202-1210.
12. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol 2010; 30: 2357-2361.
13. Fuentes QE, Fuentes QF, Andres V et al. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 2012; 24:255-262.
14. Li N. CD4+ T cells in atherosclerosis: Regulation by platelets. Thromb Haemost 2013; 109: 980-990.
15. Caudrillier A, Looney MR. Platelet-neutrophil interactions as a target for prevention and treatment of transfusion-related acute lung injury. Curr Pharm Des 2012; 18: 3260-3266.
16. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 2012; 8: 534-542.
17. Knauer KA, Fish JE, Adkinson NF Jr et al. Platelet activation in antigen-induced bronchoconstriction. N Engl J Med 1981; 305: 892-893.
18. Pitchford SC, Yano H, Lever R et al. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol 2003; 112:109-118.
19. Pitchford SC, Riffo-Vasquez Y, Sousa A et al. Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood 2004; 103: 639-647.
20. Pitchford SC, Momi S, Baglioni S et al. Allergen induces the migration of platelets to lung tissue in allergic asthma. Am J Respir Crit Care Med 2008; 177: 604-612.
21. Cattaneo M. The platelet P2 receptors. In: Michelson AD (ed). Platelets. Philadelphia: Academic Press 2013; 261-282.
22. Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature 2014; 509:310-317.
23. 1receptor in purinergic regulation of TNFα-induced vascular inflammation. Circulation 2011; 123: 2404-2413.
24. Künzli BM, Berberat PO, Giese T et al. Upregulation of CD39/NTPDases and P2receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol 2007; 292: G223-G230.
25. Lommatzsch M, Cicko S, Müller T et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 181: 928-934.
26. Cicko S, Lucattelli M, Müller T et al. Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J Immunol 2010; 185: 688-697.
27. Vanderstocken G, Bondue B, Horckmans M et al. P2Y2 receptor regulates VCAM-1 membrane and soluble forms and eosinophil accumulation during lung inflammation. J Immunol 2010; 185:3702-3707.
28. Younas M, Hue S, Lacabaratz C, Guguin A et al. IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ATP axis. J Immunol 2013; 191: 3161-3168.
29. Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 2012; 8: 437-502.
30. Müller T, Vieira RP, Grimm M et al. A potential role for P2X7R in allergic airway inflammation in mice and humans. Am J Respir Cell Mol Biol 2011; 44: 456-464.
31. Manthei DM, Jackson DJ, Evans MD et al. Protection from asthma in a high-risk birth cohort by attenuated P2X(7) function. J Allergy Clin Immunol 2012; 130: 496-502.
32. Gulbransen BD, Bashashati M, Hirota SA et al. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat Med 2012; 18: 600-604.
33. Kurashima Y, Amiya T, Nochi T et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat Commun 2012; 3: 1034.
34. Köhler D, Eckle T, Faigle M et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/ reperfusion injury. Circulation 2007; 116:1784-1794.
35. Pinsky DJ, Broekman MJ, Peschon JJ et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 2002; 109: 1031-1040.
36. Marcus AJ, Safier LB, Hajjar KA et al. Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. J Clin Invest 1991; 88: 1690-1696.
37. Hyman MC, Petrovic-Djergovic D, Visovatti SH et al. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest 2009; 119: 1136-1149.
38. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med 2012; 367: 2322-2333.
39. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014; 63:2503-2509.
40. Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol 2012; 32: 856-864.
41. Csóka B, Németh ZH, Rosenberger P et al. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. J Immunol 2010; 185: 542-550.
42. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors indownregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-920.
43. Friedman DJ, Künzli BM, A-Rahim YI et al. CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci USA 2009; 106: 16788-16793.
44. Eckle T, Füllbier L, Wehrmann M et al. Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol 2007; 178: 8127-37.
45. Léon C, Ravanat C, Freund M et al. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003; 23: 1941-1947.
46. Hermann A, Rauch BH, Braun M et al. Platelet CD40 ligand-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
47. Cattaneo M. ADP receptor antagonists. In: Michelson AD (ed). Platelets. Philadelphia: Academic Press 2013; 1117-1139.
48. Liu O, Jia L, Liu X et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. PLoS One 2012; 7:e51707.
49. Vivekananthan DP, Bhatt DL, Chew DP et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004; 94: 358-360.
50. Steinhubl SR, Badimon JJ, Bhatt DL et al. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12: 113-122.
51. Patti G, Grieco D, Dicuonzo G et al. High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation results of the ARMYDA-150 mg randomized study. J Am Coll Cardiol 2011; 57:771-778.
52. Waehre T, Damås JK, Pedersen TM et al. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost 2006; 4: 2140-2147.
53. Aukrust P. Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: Results of a double-blind placebo-controlled study. J. Thromb Haemost 2006; 4: 2140-2147.
54. Palmerini T, Barozzi C, Tomasi L et al. A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: results from the DOUBLE study. Thromb Res 2010; 125: 309-314.
55. Ostad MA, Nick E, Paixao-Gatinho V et al. Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. Clin Res Cardiol 2011; 100: 29-36.
56. Husted S, Storey RF, Harrington RA et al. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel. Clin Cardiol 2010; 33: 206-212.
57. Woodward M, Lowe GD, Francis LM et al. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: The CADET trial. J Thromb Haemost 2004; 2:1934-1940.
58. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010; 103: 71-82.
59. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006; 55: 780-784.
60. Wihlborg AK, Wang L, Braun OO et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004; 24: 1810-1815.
61. Rauch BH, Rosenkranz AC, Ermler S et al. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol 2010; 30:2434-2442.
62. Laidlaw TM, Boyce JA. Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin Exp Allergy 2012; 42: 1313-1320.
63. Samuelsson B, Dahlen SE, Lindgren JA et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237:1171-1176.
64. Hui Y, Yang G, Galczenski H, Figueroa DJ et al. The murine cysteinyl leukotriene 2 receptor. cDNA and genomic cloning, alternative splicing, and in vitro characterization. J Biol Chem 2001; 276: 47489-47495.
65. Heise CE, O'Dowd BF, Figueroa DJ et al. Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000; 275: 30531-30536.
66. Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 2013; 288: 10967-10972.
67. Hasegawa S, Ichiyama T, Hashimoto K et al. Functional expression of cysteinyl leukotriene receptors on human platelets. Platelets 2010; 21: 253-259.
68. Cattaneo M. New P2Y(12) inhibitors. Circulation 2010; 121: 171-179.
69. Paruchuri S, Tashimo H, Feng C et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206:2543-2555.
70. Cummings HE, Liu T, Feng C et al. Cutting edge:Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor. J Immunol 2013; 191: 5807-5810.
71. Nonaka Y, Hiramoto T, Fujita N. Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 2005; 337: 281-288.
72. Bunyavanich S, Boyce JA, Raby BA, Weiss ST. Gene-by-environment effect of house dust mite on purinergic receptor P2Y12 (P2RY12) and lung function in children with asthma. Clin Exp Allergy 2012; 42: 229-237.
73. Lussana F, Di Marco F, Terraneo S et al. Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study. J Thromb Haemost 2014. doi: 10.1111/jth.12779.
74. Joos GF, O'Connor B, Anderson SD et al. Indirect airway challenges. Eur Respir J 2003; 21:1050-1068.
75. Leuppi JD, Brannan JD, Anderson SD. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. Swiss Med Wkly 2002; 132: 151-158.
76. Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost 2012; 108:1031-1036.